Next Article in Journal
MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease
Next Article in Special Issue
Cardiac Roles of Serotonin (5-HT) and 5-HT-Receptors in Health and Disease
Previous Article in Journal
The Yin and Yang Effect of the Apelinergic System in Oxidative Stress
Previous Article in Special Issue
The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 5
10.3390/ijms24054749
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ergotamine Stimulates Human 5-HT4-Serotonin Receptors and Human H2-Histamine Receptors in the Heart

by
Hannes Jacob
1,
Pauline Braekow
1,
Rebecca Schwarz
1,
Christian Höhm
1,
Uwe Kirchhefer
2,
Britt Hofmann
3,
Joachim Neumann
1,* and
Ulrich Gergs
1
1
Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
2
Institute for Pharmacology and Toxicology, Medical Faculty, Westfälische Wilhelms-Universität, 48149 Münster, Germany
3
Department of Cardiac Surgery, Mid-German Heart Center, University Hospital Halle, 06120 Halle (Saale), Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(5), 4749; https://doi.org/10.3390/ijms24054749
Submission received: 21 January 2023 / Revised: 22 February 2023 / Accepted: 24 February 2023 / Published: 1 March 2023
(This article belongs to the Special Issue Serotonin Network and Energy Metabolism)
Browse Figures
Review Reports Versions Notes

Abstract

:
Ergotamine (2′-methyl-5′α-benzyl-12′-hydroxy-3′,6′,18-trioxoergotaman) is a tryptamine-related alkaloid from the fungus Claviceps purpurea. Ergotamine is used to treat migraine. Ergotamine can bind to and activate several types of 5-HT1-serotonin receptors. Based on the structural formula of ergotamine, we hypothesized that ergotamine might stimulate 5-HT4-serotonin receptors or H2-histamine receptors in the human heart. We observed that ergotamine exerted concentration- and time-dependent positive inotropic effects in isolated left atrial preparations in H2-TG (mouse which exhibits cardiac-specific overexpression of the human H2-histamine receptor). Similarly, ergotamine increased force of contraction in left atrial preparations from 5-HT4-TG (mouse which exhibits cardiac-specific overexpression of the human 5-HT4-serotonin receptor). An amount of 10 µM ergotamine increased the left ventricular force of contraction in isolated retrogradely perfused spontaneously beating heart preparations of both 5-HT4-TG and H2-TG. In the presence of the phosphodiesterase inhibitor cilostamide (1 µM), ergotamine 10 µM exerted positive inotropic effects in isolated electrically stimulated human right atrial preparations, obtained during cardiac surgery, that were attenuated by 10 µM of the H2-histamine receptor antagonist cimetidine, but not by 10 µM of the 5-HT4-serotonin receptor antagonist tropisetron. These data suggest that ergotamine is in principle an agonist at human 5-HT4-serotonin receptors as well at human H2-histamine receptors. Ergotamine acts as an agonist on H2-histamine receptors in the human atrium.

1. Introduction

Ergotamine (Figure 1B), tested in this work, is currently mainly used in the clinic for the treatment of migraine [1,2]. Ergotamine can bind to and activate 5-HT1-receptors and 5-HT2A-receptors in the brain [2]. Ergotamine can lead to hallucinations probably via these 5-HT2A-receptors [3,4]. Ergotamine can cause vasoconstriction probably because ergotamine stimulates peripheral vascular 5-HT2A-receptors and peripheral vascular α1-adrenoceptors [4]. Ergotamine is found in fungi like Claviceps pururea (Secale cornutum). Secale cornutum can be found in cereals (e.g., rye grain) and causes arterial constrictions (via stimulation of α-adrenoceptors), but possibly also hallucinations (e.g., [5,6,7,8]).
Ergotamine is formed in fungi from lysergic acid, to which, alanine, proline and phenylalanine are covalently linked [9]. No inotropic effect of ergotamine was found in isolated paced cat papillary muscle [10]. However, that might be a species problem, as H2-histamine- and 5-HT4-receptors are functionally absent in the cat heart [11,12,13]. A close derivative of ergotamine, called ergometrine (lysergic acid β-propanolamide), has, in contrast, been shown to elicit an increase in force in the guinea pig heart [14], which contains functional H2-histamine receptors [13]. The increase in force of contraction caused by ergometrine was antagonized by cimetidine, which convincingly suggested a H2-histamine receptor-mediated effect of ergometrine in the guinea pig heart [14]. Similarly, lysergic acid diethylamide (LSD) increased force of contraction in isolated guinea pig and rabbit cardiac preparations [15]. Hence, ergotamine might increase force of contraction in those species that contain functionally active H2-receptors in the heart. To the best of our knowledge, a positive inotropic cardiac effect by ergotamine in any mammalian species has never been published before. As ergotamine binds to some isoforms of peripheral serotonin-receptors [16], we hypothesized that ergotamine might stimulate human serotonin receptors in the heart. In the human heart, all inotropic and chronotropic effects of serotonin are mediated via 5-HT4-receptors [17,18]. These 5-HT4-receptors are lacking, in a functional manner, in mouse heart: serotonin failed to alter the force of contraction in isolated mouse cardiac preparations from wild type mice (WT, [19,20,21,22,23]). To facilitate the study of human 5-HT4-receptors, we had previously produced and characterized intensively transgenic mice (5-HT4-TG) with cardiac expression of this receptor only in the heart, which responded with an increase in force and frequency to serotonin [14,19,21,22]. Therefore, we decided to test the hypothesis that ergotamine would exert positive inotropic and positive chronotropic effects in these 5-HT4-TG (Figure 1A).
In the heart, four histamine receptor subtypes have been found [13]. However, species differences, regional differences and cellular differences in histamine receptor function exist in the heart [13]. In the mouse heart, histamine can only release noradrenaline [22,23,24,25,26,27,28]. Similar to the mouse, the rat, dog and cat experienced the effects of histamine resulting from a release of endogenous catecholamines [11,15,29,30,31,32].
In humans, H2-histamine receptors are present in both the atrium and ventricle (radioligand binding: [33], antibody and RNA expression: [34]). The cardiac H2-histamine receptors mediate the positive inotropic effects of histamine in isolated human atrial cardiac preparations [35,36,37]. Therefore, we have generated transgenic mice that overexpress the H2-histamine receptors only in the heart (H2-TG), wherein histamine increases force of contraction [22,23,24,25,26,27,28].
Hence, we tested the following hypotheses: ergotamine might increase force of contraction in 5-HT4-TG and/or in H2-TG, and in human atrial preparations via HT4- and/or H2-receptors. Progress reports have been published in abstract form [38].

2. Results

2.1. H2-TG Atrium

2.1.1. Left Atrium

We noticed that ergotamine time- and concentration-dependently increased force of contraction in H2-TG. A typical original recording is seen in Figure 2A. For comparison, we studied WT. In WT, ergotamine failed to increase force of contraction (Figure 2B). In H2-TG additionally applied histamine, force of contraction further failed to increase (Figure 2A), while additionally applied histamine was ineffective in left atrium from WT (Figure 2B). Summarizing the results, one can see that ergotamine concentration-dependently increased force of contraction in left atrial preparations (Figure 2C). Moreover, ergotamine concentration-dependently shortened the time to peak tension (Figure 2D). This shortening was so extensive that additionally applied histamine could not shorten time to peak tension any further. In a similar fashion, ergotamine hastened time of relaxation concentration-dependently (Figure 2E) and additionally applied histamine was not more effective to shorten time of relaxation (Figure 2E). In addition, ergotamine also concentration dependently enhanced the absolute value of the rate-of-tension development (Figure 2F) and the rate-of-tension relaxation, and this effect of ergotamine was maximal because additionally applied histamine augmented these parameters no further. Hence, ergotamine acted as a full agonist at H2-histamine receptors under these conditions (Figure 2G).

2.1.2. Right Atrium

In right atrial preparations from H2-TG, ergotamine increased the beating rate as seen in an original recording (Figure 3A). Additionally applied histamine did not increase the beating rate any further (Figure 3A). Ergotamine failed to increase the beating rate in WT. Several such experiments are summarized in Figure 3B.

2.2. 5-HT4-TG

2.2.1. Left Atrium

We noticed that ergotamine time- and concentration-dependently increased force of contraction in 5-HT4-TG left atria. A typical original recording is seen in Figure 4A. For comparison, we studied WT: here, ergotamine failed to increase force of contraction (Figure 4B). In 5-HT4-TG, additionally applied 5-HT increased force of contraction further (Figure 2A), while ergotamine and 5-HT were ineffective in left atrium from WT (Figure 4B). Summarizing the results, one can see that ergotamine concentration-dependently increased force of contraction in left atrial preparations from 5-HT4-TG (Figure 4C). Moreover, ergotamine concentration-dependently shortened the time of tension in 5-HT4-TG (Figure 4D). This shortening was so extensive that additionally applied serotonin could not shorten time to peak tension any further. In a similar fashion, ergotamine hastened time of relaxation concentration-dependently (Figure 4E) and additionally applied histamine was not more effective to reduce time of relaxation (Figure 4E) in 5-HT4-TG. In addition, ergotamine also concentration-dependently enhanced the absolute value of the rate-of-tension development (Figure 4F) and the rate-of-tension relaxation (Figure 4G) in 5-HT4-TG.

2.2.2. Right Atrium

In right atrial preparations from 5-HT4-TG, ergotamine increased the beating rate as seen in an original recording (Figure 5A). Additionally applied serotonin hardly increased the beating rate any further in 5-HT4-TG (Figure 5A). Ergotamine failed to increase the beating rate in WT. Several such experiments are summarized in Figure 5B: Ergotamine concentration-dependently increased the beating rate in isolated right atrial preparations (Figure 5B). This effect was also antagonized by subsequently applied tropisetron.

2.3. Isolated Perfused Hearts

It was interesting to study whether ergotamine might affect left ventricular function, because in the mouse and human heart, the left ventricle is decisive for the perfusion of the organs of the body. Therefore, we perfused retrogradely isolated spontaneously beating whole hearts (Langendorff procedure) from H2-TG, 5-HT4-TG and WT with ergotamine. In brief, ergotamine (10 µM) increased left ventricular force of contraction and the rate-of-tension relaxation in the apex of hearts from H2-TG, 5-HT4-TG but not from WT (Table 1). Thus, the effects of ergotamine are not confined to the atrium but also present in the ventricle of the transgenic animals studied here.

2.4. Phosphorylation

In separate experiments, we tested the effects of ergotamine on the phosphorylation state of phospholamban in left auricular heart samples from H2-TG and 5-HT4-TG. These left atrial samples were electrically stimulated, and at the end of the concentration–response curves (10 µM ergotamine), the atria were frozen in liquid nitrogen. It turned out that ergotamine increased the phosphorylation state of phospholamban at the amino acid serine 16 in H2-TG and 5-HT4-TG compared to WT atrial preparations (Figure 6), suggesting a stimulation of cAMP-dependent protein kinases (Figure 1A).

2.5. Human Atrial Contraction

To find out whether our data are relevant in the human heart and thus clinically relevant, we performed the next contraction experiments in human cardiac preparations. In isolated electrically driven right atrial preparations, cilostamide, a phosphodiesterase III inhibitor, raised force of contraction to some extent. After this pre-stimulation, additionally applied ergotamine increased force of contraction further. This is exemplified in the original recording depicted in Figure 7. The mean data are put together in Figure 8 and depict this increase. Thereafter, the question arose whether the H2- or the 5-HT4-receptor mediated these effects. Therefore, we additionally applied first tropisetron to block 5-HT4- and thereafter cimetidine to block H2-receptors. As depicted in Figure 7 and summarized in Figure 8, the positive inotropic effect of ergotamine was not sensitive to tropisetron, but sensitive to additionally applied cimetidine. Based on these data, we would regard the positive inotropic effect of ergotamine in the human right atrium as H2-receptor-mediated.

3. Discussion

3.1. Main New Findings

The main new findings in this report as per the observation is that ergotamine can act as a functional agonist at both human 5-HT4- and human H2-receptors in the heart of appropriate transgenic mouse models. Importantly, ergotamine only uses H2-receptors to increase contractility in the human heart, specifically the human isolated atrium.

3.2. 5-HT4-Receptors

Looking at the chemical structure of ergotamine and knowing that it was synthesized from ergot constituents [9], knowing also that ergotamine can act on 5-HT2A-receptors in the periphery, we hypothesized that ergotamine might stimulate human cardiac serotonin receptors. In the human heart, serotonin only increases force via 5-HT4-receptors. Hence, we thought that ergotamine might stimulate 5-HT4 receptors in the human heart. As a first step, we used as a model our 5-HT4-TG [19]. Indeed, we noted a positive inotropic effect of ergotamine in the atrium and ventricle of 5-HT4-TG. In atrial preparations, we could show that ergotamine is less effective than serotonin and is thus functionally a partial agonist at 5-HT4-receptors because additionally applied serotonin raised the force further. The observations were different in right atrium, here, ergotamine was of similar efficacy as serotonin, and thus can be viewed as a full agonist. The reason for this discrepancy is unclear. One attractive hypothesis is that the overexpression of 5-HT4-receptors is higher in the sinus node than in the left atrium. However, this issue was beyond the scope of the present work.

3.3. H2-Receptors

It might be asked why we chose to study H2-TG. In other words, why should ergotamine stimulate cardiac histamine receptors? One could argue from a chemical point of view. If you look carefully at the structural formula of ergotamine (Figure 1B), you might discern an azole ring similar to the imidazole ring in histamine. In addition, we noted that ergometrine, a closely related lysergic acid derivative, can activate cardiac H2-receptors in guinea pig Langendorff-perfused hearts [14]. Moreover, LSD, or lysergic acid diethylamide, the well-known hallucinogenic drug also closely related to ergotamine, can stimulate rabbit H2-receptors and guinea pig H2-receptors in cardiac preparations [15]. Hence, we thought it worthwhile to test ergotamine in our H2-TG model system [23]. We noted that in H2-TG, as in guinea pig hearts and rabbit hearts [15], ergotamine acted as a partial functional agonist with regard to force of contraction. Moreover, as additionally applied histamine in atrial preparations from H2-TG hardly increased force or frequency above values reached by ergotamine itself, we would regard ergotamine as a fully functional agonist—with respect to force and beating rate at human H2-receptors expressed in the heart of H2-TG.

3.4. Mechanism of Ergotamine

Our assumption is that ergotamine acts as an agonist at cardiac human H2-histamine receptors because ergotamine increases force and beating rate only in atrium from H2-TG and not in WT. Likewise, we suggest ergotamine increases force and beating rate as an agonist at cardiac human 5-HT4-receptors because ergotamine only increases contractility in atrium from 5-HT4-TG and not in WT. Clearly, under our experimental conditions, ergotamine is a dual agonist at two receptors. One might hypothesize that the tryptamine ring of ergotamine binds to the binding pocket for tryptamine at the human 5-HT4-receptor. On the other hand, it can be claimed that the azole ring of ergotamine binds at the appropriate pocket of the human H2- receptors. There is sound evidence from crystallographic studies that ergotamine can bind with different functional groups to different receptors, but, in this case, to 5-HT2A-receptors and 5-HT2B-receptors [39]. Hence, there is precedence for our hypothesis.
Moreover, there are data on a functional interaction of H2-receptors and 5-HT4 receptors in human atrial tissue. Even the order of drug application was relevant. In more detail, when we first applied an increasing concentration of 5-HT, a positive inotropic effect followed. When we subsequently deposited histamine in increasing concentrations to the organ bath, the force declined. We speculated that this might mean that H2-receptors, context-dependently, can couple to first inhibitory and then stimulatory GTP-binding proteins, leading to a decrease and then increase in cAMP levels and therefore force of contraction [22]. One might speculate that such an effect might also be induced by ergotamine.

3.5. Role of Phosphorylation of Regulatory Proteins

Any sufficiently large H2-receptor stimulation or 5-HT4-receptor stimulation leads to an increase in the phosphorylation state of regulatory proteins that are substrates for the cAMP-dependent protein kinase [18,26]. Indeed, we described similar to others that histamine acting via H2-receptors in the heart can increase the phosphorylation state of phospholamban [40] in H2-TG and the human atrium [13]. Likewise, we and others reported that serotonin via 5-HT4-receptors can increase protein phosphorylation in 5-HT4-TG and human atrium [19,41,42]. For instance, serotonin increased the phosphorylation state of phospholamban in the isolated human atrial strips [42]. We extend here our previous studies by showing the ergotamine increase in H2-TG and in 5-HT4-TG the phosphorylation state of phospholamban. These phosphorylations can explain, at least in part, why ergotamine increased the relaxation rate in atrial and ventricular preparations from H2-TG and 5-HT4-TG.

3.6. Contractile Role of Ergotamine in Human Atrium

Interestingly, ergotamine acted only as an agonist at H2-agonist and not at 5-HT4-receptors in the isolated human atrium. One hypothetical explanation would be that the density of the overexpressed receptors is very high for 5-HT4-serotonin receptors in transgenic mouse atrium (5-HT4-TG), much higher than in the human heart. Usually, if the receptor is more highly expressed in a cell, less agonist is needed to stimulate this receptor. In other words, 5-HT4-TG is a very sensitive system to detect actions of drugs on human 5-HT4-receptors. Alternatively, if a drug does not stimulate 5-HT4-receptors in 5-HT4-TG, this drug is unlikely to increase human cardiac force via 5-HT4-receptors. We have mRNA data that indicate a thousand-fold overexpression of the 5-HT4 receptor in the heart from 5-HT4-TG [22]. However, these were non-failing mouse hearts and we do not know how the H2-receptor or 5-HT4 receptor expression might change in failing mouse hearts, as has been reported for failing rat hearts; in these failing rat hearts the mRNA for the 5-H4 receptor increased over time [43]. Indeed, binding is hardly detectible with radioligands of 5-HT4-receptors in human hearts, whereas expression of H2 in human hearts is easily measurable with ligand binding and is quite high [17,33]; thus, this is a plausible, albeit hypothetical, explanation for our data in the human atrium. Another explanation would be the partial agonistic effect of ergotamine on force of contraction in atrial preparations from 5-HT4-TG. In other words, the intrinsic activity of ergotamine for 5-HT4-receptors is lower than that of 5-HT. This second observation might also contribute to the missing effect of ergotamine in human atrium via 5-HT4-receptors. Hence, we tentatively conclude that in vivo effects of ergotamine in the human heart on force of contraction are more likely mediated by H2-histamine and not by 5-HT4–receptors.

3.7. Clinical Relevance

We would predict that a tachycardia after treatment with ergotamine in patients could be blocked by cimetidine, an approved drug. However, this prediction needs to be confirmed in a clinical study. Peak therapeutic plasma levels of ergotamine around 0.69 nM have been cited [44]. In intoxications in humans, much higher plasma levels of ergotamine, such as 0.015 µM, have been communicated [5]. Moreover, ergotamine is degraded by CYP2D6. Drugs that inhibit the activity of CYP2D6 could thus increase plasma levels of ergotamine. Indeed, some cases of ergotamine intoxication have been reported when patients were also given in addition to ergotamine other drugs that are inhibitors of CYP2D6 [45]. In addition, high ergotamine levels in plasma should occur in patients with a defective polymorphism of CYP2D6, because then less ergotamine will be degraded. In summary, there are various clinical situations where high plasma concentrations of ergotamine are reached. Under these high concentrations of ergotamine, H2-receptors in the heart might be stimulated by ergotamine. This stimulation of H2-receptors can lead to cardiac arrhythmias [13]. There are case reports that ergotamine taken in dosage to treat migraine can lead to an acute coronary syndrome and to arrhythmias in patients [46,47]. Based on our data, and with confidence, one could try cimetidine in such patients to terminate arrhythmias, namely atrial fibrillation.

3.8. Limitations of the Study

We have not tested the effects on the sinus node of man directly. Such a study would require access to the human pacemaker or corresponding stem cells. Such studies were beyond the scope of this initial study. We did not have the opportunity to study contractility in human left ventricular tissue for lack of access to that tissue. However, we argue that our studies in Langendorff-perfused hearts make it at least likely that ergotamine is also an agonist in the human left ventricle. Moreover, we cannot provide molecular information in which parts of the ergotamine molecule can interact with the H2-receptor or the 5-HT4-receptor. To this end, crystallographic studies would be required in subsequent work.

4. Materials and Methods

4.1. Transgenic Mice

The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Research Council (2011) [48]. Animals were maintained and handled according to approved protocols of the animal welfare committees of the University of Halle-Wittenberg, Germany. The generation and initial characterization of the transgenic mice were described before [19,23]. In brief, the human H2–histamine-receptor cDNA or the human 5-HT4-serotonin-receptor cDNA together with a C-terminal 6xhistidine tag were cut from the parent plasmid and inserted into the Eco ICR site of a mouse cardiac α-myosin heavy chain promoter expression cassette. For all experiments, 12–30 weeks-old transgenic mice and WT littermates of both sexes were used.

4.2. Contractile Studies in Mice

As reported often before, right or left atrial preparations from mice were isolated and mounted in organ baths (e.g., [20]). The buffer in the 10 mL-organ baths contained 119.8 mM NaCI, 5.4 mM KCI, 1.8 mM CaCl2, 1.05 mM MgCl2, 0.42 mM NaH2PO4, 22.6 mM NaHCO3, 0.05 mM Na2EDTA, 0.28 mM ascorbic acid and 5.05 mM glucose. The solution was continuously gassed with 95% O2 and 5% CO2 and maintained at 37 °C and pH 7.4 [20]. Spontaneously beating right atrial preparations from mice were used to study the intrinsic beating rate. The drug application was as follows. After equilibration was reached, ergotamine was cumulatively added to left atrial or right atrial preparations to establish concentration–response curves. Then, where indicated, either serotonin or histamine were additionally applied to the preparations (Figure 1B).

4.3. Contractile Studies on Human Preparations

The contractile studies on human preparations were done using the same setup and buffer as used in the mouse studies (see Section 2.2). The samples were obtained from sixteen patients. Fifteen patients were male and one patient was female. The mean age was 71 ± 10 years. Patient suffered from three vessel coronary heart disease and underwent bypass surgery. Drug therapy included metoprolol, furosemide, apixaban and acetyl salicylic acid. Our methods used for atrial contraction studies in human samples have been previously published and were not altered in this study [27].

4.4. Isolated Perfused Hearts

As described repeatedly from our group [19,23], isolated whole mouse hearts were retrogradely perfused with the same buffer as in Section 4.2 above. Hearts were allowed to beat by themselves. Force was monitored from the apex cordis by a hook connected to an electronic force monitor and digitized. Perfusion with drugs took place with a syringe connected to a pump. This pump was connected as a bypass to the aorta. At the end of the experiments, hearts were rapidly brought to the temperature of liquid nitrogen to stop any phosphorylation or dephosphorylation reactions. Frozen samples were kept at −80 °C until biochemical analysis.

4.5. Western Blotting

The homogenization of the samples, protein measurements, electrophoresis, primary and secondary antibody incubation and quantification were performed following our previously established protocols [23]. First antibodies were anti-calsequestrin (CSQ) antibody, Santa Cruz #sc390999 (diluted 1:20,000) and anti-phospholamban (pSer16) antibody, Badrilla A-010-12 (diluted 1:5000).

4.6. Data Analysis

Data shown are means ± standard error of the mean. Statistical significance was estimated using the analysis of variance followed by Bonferroni’s t-test or the Student’s t-test as appropriate. A p-value < 0.05 was considered to be significant.

4.7. Drugs and Materials

The ergotamine was in dissolved dimethylsulfoxide (DMSO), serotonin and histamine were dissolved in water and were purchased from Sigma-Aldrich (Germany). All other chemicals were of the highest purity grade commercially available. Deionized water was used throughout the experiments. Stock solutions were prepared fresh daily.

5. Conclusions

We can now answer the questions raised in the introduction in the following way: ergotamine increases force of contraction in both 5-HT4-TG and in H2-TG. In human atrial preparations, ergotamine increases force of contraction via the H2-receptors and not via 5-HT4-receptors.

Author Contributions

J.N. and U.G. conceived and designed the research. B.H. supplied reagents and clinical data. H.J., P.B., R.S., C.H. and J.N. performed experiments. H.J., P.B., R.S., J.N. and U.G. analyzed and plotted data. J.N., U.G. and U.K. wrote the first draft and revised the manuscript. The authors declare that all data were generated in-house and that no paper mill was used. All authors have read and agreed to the published version of the manuscript.

Funding

Supported by the Deutsche Forschungsgemeinschaft (DFG).

Institutional Review Board Statement

Animals: The investigation conformed to the Guide for the Care and Use of Laboratory Animals as published by the National Research Council (2011). The animals were handled and maintained according to the approved protocols of the Animal Welfare Committee of the University of Halle-Wittenberg, Halle, Germany. Humans: This study in patients complies with the Declaration of Helsinki and has been approved by the local ethics committee (hm-bü 4 August 2005).

Informed Consent Statement

Informed written consent was obtained from all patients included in the study.

Data Availability Statement

The data of this study are available from the corresponding author upon reasonable request.

Acknowledgments

We thank P. Willmy for technical assistance. This work contains parts of the medical theses of P.B. and H.J.

Conflicts of Interest

All authors declare no competing financial or non-financial or personal interests.

References

  1. Nguyen, J.L.; Munshi, K.; Peasah, S.K.; Swart, E.C.S.; Kohli, M.; Henderson, R.; Good, C.B. Trends in utilization and costs of migraine medications, 2017–2020. J. Headache Pain 2022, 23, 111. [Google Scholar] [CrossRef] [PubMed]
  2. Ngo, M.; Tadi, P. Ergotamine/Caffeine. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
  3. Gulbranson, S.H.; Mock, R.E.; Wolfrey, J.D. Possible Ergotamine-Caffeine–Associated Delirium. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2002, 22, 126–129. [Google Scholar] [CrossRef] [PubMed]
  4. Silberstein, S.D.; McCrory, D. Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy. Headache 2003, 43, 144–166. [Google Scholar] [CrossRef] [PubMed]
  5. Stange, K.; Pohlmeier, H.; Lübbesmeyer, A.; Gumbinger, G.; Schmitz, W.; Baumgart, P. Vaskulärer Ergotismus durch Getreidestaubinhalation [Vascular ergotism through inhalation of grain dust]. Dtsch. Med. Wochenschr. 1998, 123, 1547–1550. [Google Scholar] [CrossRef] [PubMed]
  6. McGrath, M.A.; Liegl, C.A. Ergotism: Case Report and Review of the Literature. Int. J. Angiol. 2016, 25, e8–e11. [Google Scholar] [CrossRef] [Green Version]
  7. Cervellin, G.; Longobardi, U.; Lippi, G. One holy man, one eponym, three distinct diseases. St. Anthonys Fire Revisited. Acta Biomed. 2020, 92, e2021008. [Google Scholar] [CrossRef] [PubMed]
  8. Huybrechts, B.; Malysheva, S.V.; Masquelier, J. A Targeted UHPLC-MS/MS Method Validated for the Quantification of Ergot Alkaloids in Cereal-Based Baby Food from the Belgian Market. Toxins 2021, 13, 531. [Google Scholar] [CrossRef]
  9. Jamieson, C.S.; Misa, J.; Tang, Y.; Billingsley, J.M. Biosynthesis and synthetic biology of psychoactive natural products. Chem. Soc. Rev. 2021, 50, 6950–7008. [Google Scholar] [CrossRef]
  10. Rabinowitz, B.; Chuck, L.; Kligerman, M.; Parmley, W.W. Positive inotropic effects of methoxamine: Evidence for alpha-adrenergic receptors in ventricular myocardium. Am. J. Physiol. Content 1975, 229, 582–585. [Google Scholar] [CrossRef] [Green Version]
  11. Laher, I.; McNeill, J.H. Effects of histamine on rat isolated atria. Can. J. Physiol. Pharmacol. 1980, 58, 1114–1116. [Google Scholar] [CrossRef]
  12. Laher, I.; McNeill, J.H. Effects of histamine in the isolated kitten heart. Can. J. Physiol. Pharmacol. 1980, 58, 1256–1261. [Google Scholar] [CrossRef] [PubMed]
  13. Neumann, J.; Kirchhefer, U.; Dhein, S.; Hofmann, B.; Gergs, U. The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions. Front. Pharmacol. 2021, 12, 732842. [Google Scholar] [CrossRef] [PubMed]
  14. Bongrani, S.; Di Donato, M.; Visioli, O.; Mantovani, P. Effect of ergometrine on contractile force of guinea-pig isolated heart: Antagonism by cimetidine. Agents Actions 1979, 9, 15–17. [Google Scholar] [CrossRef] [PubMed]
  15. Angus, J.A.; Black, J.W. Pharmacological assay of cardiac H2-receptor blockade by amitriptyline and lysergic acid diethylamide. Circ. Res. 1980, 46 Pt 2, I64–I69. [Google Scholar]
  16. Cortijo, J.; Martí-Cabrera, M.; Bernabeu, E.; Domènech, T.; Bou, J.; Fernández, A.G.; Beleta, J.; Palacios, J.M.; Morcillo, E. Characterization of 5-HT receptors on human pulmonary artery and vein: Functional and binding studies. Br. J. Pharmacol. 1997, 122, 1455–1463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Kaumann, A.J.; Levy, F.O. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 2006, 111, 674–706. [Google Scholar] [CrossRef] [PubMed]
  18. Neumann, J.; Hofmann, B.; Gergs, U. Production and function of serotonin in cardiac cells. In Serotonin—A Chemical Messenger Between All Types of Living Cells; Kaneez, F.S., Ed.; Intech: Rijeka, Croatia, 2017; Chapter 13; pp. 271–305. ISBN 978-953-51-3361-2. [Google Scholar]
  19. Gergs, U.; Baumann, M.; Böckler, A.; Buchwalow, I.B.; Ebelt, H.; Fabritz, L.; Hauptmann, S.; Keller, N.; Kirchhof, P.; Klöckner, U.; et al. Cardiac overexpression of the human 5-HT4receptor in mice. Am. J. Physiol. Circ. Physiol. 2010, 299, H788–H798. [Google Scholar] [CrossRef] [Green Version]
  20. Gergs, U.; Böckler, A.; Ebelt, H.; Hauptmann, S.; Keller, N.; Otto, V.; Pönicke, K.; Schmitz, W.; Neumann, J. Human 5-HT4 receptor stimulation in atria of transgenic mice. Naunyn-Schmiedebergs Arch. Pharmacol. 2013, 386, 357–367. [Google Scholar] [CrossRef]
  21. Neumann, J.; Käufler, B.; Gergs, U. Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice? Naunyn-Schmiedebergs Arch. Pharmacol. 2019, 392, 991–1004. [Google Scholar] [CrossRef]
  22. Neumann, J.; Schwarzer, D.; Fehse, C.; Schwarz, R.; Marusakova, M.; Kirchhefer, U.; Hofmann, B.; Gergs, U. Functional interaction of H2-receptors and 5HT4-receptors in atrial tissues isolated from double transgenic mice and from human patients. Naunyn-Schmiedebergs Arch. Pharmacol. 2021, 394, 2401–2418. [Google Scholar] [CrossRef]
  23. Gergs, U.; Bernhardt, G.; Buchwalow, I.B.; Edler, H.; Fröba, J.; Keller, M.; Kirchhefer, U.; Köhler, F.; Mißlinger, N.; Wache, H.; et al. Initial Characterization of Transgenic Mice Overexpressing Human Histamine H2Receptors. J. Pharmacol. Exp. Ther. 2019, 369, 129–141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Gergs, U.; Kirchhefer, U.; Bergmann, F.; Künstler, B.; Mißlinger, N.; Au, B.; Mahnkopf, M.; Wache, H.; Neumann, J. Characterization of Stressed Transgenic Mice Overexpressing H2-Histamine Receptors in the Heart. J. Pharmacol. Exp. Ther. 2020, 374, 479–488. [Google Scholar] [CrossRef] [PubMed]
  25. Gergs, U.; Büxel, M.L.; Bresinsky, M.; Kirchhefer, U.; Fehse, C.; Höring, C.; Hofmann, B.; Marušáková, M.; Čináková, A.; Schwarz, R.; et al. Cardiac Effects of Novel Histamine H2 Receptor Agonists. J. Pharm. Exp. Ther. 2021, 379, 223–234. [Google Scholar] [CrossRef] [PubMed]
  26. Neumann, J.; Voss, R.; Laufs, U.; Werner, C.; Gergs, U. Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H2-histamine-receptor activation in isolated atria of transgenic mice. Naunyn-Schmiedebergs Arch. Pharmacol. 2021, 394, 1215–1229. [Google Scholar] [CrossRef]
  27. Neumann, J.; Binter, M.B.; Fehse, C.; Marušáková, M.; Büxel, M.L.; Kirchhefer, U.; Hofmann, B.; Gergs, U. Amitriptyline functionally antagonizes cardiac H2 histamine receptors in transgenic mice and human atria. Naunyn-Schmiedebergs Arch. Pharmacol. 2021, 394, 1251–1262. [Google Scholar] [CrossRef]
  28. Neumann, J.; Grobe, J.M.; Weisgut, J.; Schwelberger, H.G.; Fogel, W.A.; Marušáková, M.; Wache, H.; Bähre, H.; Buchwalow, I.B.; Dhein, S.; et al. Histamine can be Formed and Degraded in the Human and Mouse Heart. Front. Pharmacol. 2021, 12, 582916. [Google Scholar] [CrossRef]
  29. Flacke, W.; Atanacković, D.; Gillis, R.A.; Alper, M.H. The actions of histamine on the mammalian heart. J. Pharmacol. Exp. Ther. 1967, 155, 271–278. [Google Scholar]
  30. Dai, S. A study of the actions of histamine on the isolated rat heart. Clin. Exp. Pharm. Physiol. 1976, 3, 359–367. [Google Scholar] [CrossRef]
  31. Bartlet, A.L. The action of histamine in the isolated heart. Br. J. Pharm. Chemother. 1963, 21, 450–461. [Google Scholar] [CrossRef] [Green Version]
  32. Wellner-Kienitz, M.C.; Bender, K.; Meyer, T.; Pott, L. Coupling to Gs and G(q/11) of histamine H2 receptors heterologously expressed in adult rat atrial myocytes. Biochim. Biophys. Acta 2003, 1642, 67–77. [Google Scholar] [CrossRef]
  33. Baumann, G.; Mercader, D.; Busch, U.; Felix, S.B.; Loher, U.; Ludwig, L.; Sebening, H.; Heidecke, C.D.; Hagl, S.; Sebening, F.; et al. Effects of the H2-receptor agonist impromidine in human myocardium from patients with heart failure due to mitral and aortic valve disease. J. Cardiovasc. Pharmacol. 1983, 5, 618–625. [Google Scholar] [CrossRef] [PubMed]
  34. Matsuda, N.; Jesmin, S.; Takahashi, Y.; Hatta, E.; Kobayashi, M.; Matsuyama, K.; Kawakami, N.; Sakuma, I.; Gando, S.; Fukui, H.; et al. Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J. Pharm. Exp. Ther. 2004, 309, 786–795. [Google Scholar] [CrossRef] [PubMed]
  35. Levi, R.; Malm, J.R.; Bowman, F.O.; Rosen, M.R. The arrhythmogenic actions of histamine on human atrial fibers. Circ. Res. 1981, 49, 545–550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Genovese, A.; Gross, S.S.; Sakuma, I.; Levi, R. Adenosine promotes histamine H1-mediated negative chronotropic and inotropic effects on human atrial myocardium. J. Pharm. Exp. Ther. 1988, 247, 844–849. [Google Scholar]
  37. Zerkowski, H.R.; Broede, A.; Kunde, K.; Hillemann, S.; Schäfer, E.; Vogelsang, M.; Michel, M.C.; Brodde, O.E. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedebergs Arch. Pharmacol. 1993, 347, 347–352. [Google Scholar] [CrossRef] [PubMed]
  38. Jacob, H.; Braekow, P.; Höhm, C.; Gergs, U.; Hofmann, B.; Kirchhefer, U.; Humphrys, L.; Pockes, S.; Neumann, J. Effects of ergotamine, ergometrine and LSD on mouse and human atrial preparations. Naunyn-Schmiedebergs Arch. Pharm. 2023, in press. [Google Scholar]
  39. Wang, C.; Jiang, Y.; Ma, J.; Wu, H.; Wacker, D.; Katritch, V.; Han, G.W.; Liu, W.; Huang, X.P.; Vardy, E.; et al. Structural basis for molecular recognition at serotonin receptors. Science 2013, 340, 610–614. [Google Scholar] [CrossRef] [Green Version]
  40. Simmerman, H.K.; Collins, J.H.; Theibert, J.L.; Wegener, A.D.; Jones, L.R. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J. Biol. Chem. 1986, 261, 13333–13341. [Google Scholar] [CrossRef]
  41. Christ, T.; Rozmaritsa, N.; Engel, A.; Berk, E.; Knaut, M.; Metzner, K.; Canteras, M.; Ravens, U.; Kaumann, A. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc. Natl. Acad. Sci. USA 2014, 111, 11193–11198, Erratum in Proc. Natl. Acad. Sci. USA 2014, 111, 14003. [Google Scholar] [CrossRef] [Green Version]
  42. Gergs, U.; Neumann, J.; Simm, A.; Silber, R.E.; Remmers, F.O.; Läer, S. Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium. Naunyn-Schmiedebergs Arch. Pharmacol. 2009, 379, 349–359. [Google Scholar] [CrossRef]
  43. Brattelid, T.; Qvigstad, E.; Lynham, J.A.; Molenaar, P.; Aass, H.; Geiran, O.; Skomedal, T.; Osnes, J.B.; Levy, F.O.; Kaumann, A.J. Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmiedebergs Arch. Pharmacol. 2004, 370, 157–166. [Google Scholar] [CrossRef] [PubMed]
  44. Sanders, S.W.; Haering, N.; Mosberg, H.; Jaeger, H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur. J. Clin. Pharmacol. 1986, 30, 331–334. [Google Scholar] [CrossRef] [PubMed]
  45. Mohamedi, N.; Mirault, T.; Durivage, A.; Di Primio, M.; Khider, L.; Detriche, G.; El Batti, S.; Sapoval, M.; Messas, E.; Goudot, G. Ergotism with acute limb ischemia, provoked by HIV protease inhibitors interaction with ergotamine, rescued by multisite transluminal balloon angioplasty. J. Med. Vasc. 2021, 46, 13–21. [Google Scholar] [CrossRef] [PubMed]
  46. Velez Roa, S.; Preumont, N.; Mols, P.; Stoupel, E.; Renard, M. Ventricular fibrillation secondary to ergotamine in a healthy young woman. Acta Cardiol. 1999, 54, 283–286. [Google Scholar]
  47. Okutucu, S.; Karakulak, U.N.; Kabakcı, G.; Aytemir, K. An unusual cause of chest pain: Acute coronary syndrome following administration of ergotamine tartrate. Exp. Clin. Cardiol. 2012, 17, 43–44. [Google Scholar]
  48. National Research Council. Guide for the Care and Use of Laboratory Animals, 8th ed.; The National Academies Press: Washington, DC, USA, 2011. [Google Scholar]
Ijms 24 04749 g001 550
Figure 1. (A) Signal transduction: Serotonin activates and tropisetron antagonizes 5-HT4-receptors in the sarcolemma. Histamine activates and cimetidine antagonizes H2-receptors in the sarcolemma. Ergotamine can activate both receptors. Activation of these receptors lead via GTP binding stimulatory protein (Gs) an increased activity of adenylyl cyclases (AC). Thereby, more cAMP is generated. The formed cAMP is finally degraded by phosphodiesterases (PDE). The cAMP can activate cAMP-dependent kinases (PKA) that phosphorylate and activate target proteins in the heart. These included the L-type Ca channel (LTCC) that facilitates the entry of “trigger” Ca ion into the cell. Here, Ca ions can bind to myofilaments. Phosphorylation of the troponin inhibitor (TnI) or phospholamban (PLB) hasten cardiac relaxation. For instance, phosphorylation of PLB allows SERCA to pump more Ca ions from the cytosol into the sarcoplasmic reticulum. In the sarcoplasmic reticulum, Ca ions bind to calsequestrin (CSQ). The ryanodine receptor upon phosphorylation will allow more Ca ions to leave the sarcoplasmic reticulum and enter the cytosol. (B) Structural similarities: There are structural similarities between serotonin and ergotamine or histamine and ergotamine. Compare the azole ring in ergotamine to the imidazole ring in histamine. Compare the indole ring in ergotamine with the indole ring in serotonin. This may explain the activation of both receptors in (A) by ergotamine.
Figure 1. (A) Signal transduction: Serotonin activates and tropisetron antagonizes 5-HT4-receptors in the sarcolemma. Histamine activates and cimetidine antagonizes H2-receptors in the sarcolemma. Ergotamine can activate both receptors. Activation of these receptors lead via GTP binding stimulatory protein (Gs) an increased activity of adenylyl cyclases (AC). Thereby, more cAMP is generated. The formed cAMP is finally degraded by phosphodiesterases (PDE). The cAMP can activate cAMP-dependent kinases (PKA) that phosphorylate and activate target proteins in the heart. These included the L-type Ca channel (LTCC) that facilitates the entry of “trigger” Ca ion into the cell. Here, Ca ions can bind to myofilaments. Phosphorylation of the troponin inhibitor (TnI) or phospholamban (PLB) hasten cardiac relaxation. For instance, phosphorylation of PLB allows SERCA to pump more Ca ions from the cytosol into the sarcoplasmic reticulum. In the sarcoplasmic reticulum, Ca ions bind to calsequestrin (CSQ). The ryanodine receptor upon phosphorylation will allow more Ca ions to leave the sarcoplasmic reticulum and enter the cytosol. (B) Structural similarities: There are structural similarities between serotonin and ergotamine or histamine and ergotamine. Compare the azole ring in ergotamine to the imidazole ring in histamine. Compare the indole ring in ergotamine with the indole ring in serotonin. This may explain the activation of both receptors in (A) by ergotamine.
Ijms 24 04749 g001
Ijms 24 04749 g002a 550Ijms 24 04749 g002b 550Ijms 24 04749 g002c 550Ijms 24 04749 g002d 550
Figure 2. Ergotamine increases force in H2-TG. (A) Original recording in mouse left atrial preparations from H2-TG. It becomes apparent that ergotamine induced a time- and concentration-dependent positive inotropic effect. Black triangles indicate addition of ergotamine. Gray triangles indicate addition of histamine. (B) Original recordings in mouse left atrial preparations from WT. It becomes apparent that ergotamine did not induce a time- and concentration-dependent positive inotropic effect. (C) Summarized concentration–response curves for the effect of ergotamine or histamine on force of contraction. (D: T1) Time to peak tension. (E: T2) Time to relaxation. (F: dF/dtmax) Rate-of-tension development. (G: dF/dtmin) Rate-of-tension relaxation in H2-TG left atrial preparations. Ordinates in (A–C): force of contraction in milli-Newton (mN). Ordinate in (D) time to peak tension in milli seconds (ms). Ordinate in (E) time of relaxation in milli seconds (ms). Ordinate in (F) rate of contraction in mN/s and ordinate in (G) rate of relaxation in mN/s. Horizontal bars in (A,B) indicate time in minutes (min). Abscissae in (D–F) indicate concentrations of ergotamine or histamine in negative decadic logarithm of molar concentrations. * p < 0.05 vs. Ctr, first significant difference versus control (pre-drug value, Ctr). “n” indicates number of experiments given in brackets.
Figure 2. Ergotamine increases force in H2-TG. (A) Original recording in mouse left atrial preparations from H2-TG. It becomes apparent that ergotamine induced a time- and concentration-dependent positive inotropic effect. Black triangles indicate addition of ergotamine. Gray triangles indicate addition of histamine. (B) Original recordings in mouse left atrial preparations from WT. It becomes apparent that ergotamine did not induce a time- and concentration-dependent positive inotropic effect. (C) Summarized concentration–response curves for the effect of ergotamine or histamine on force of contraction. (D: T1) Time to peak tension. (E: T2) Time to relaxation. (F: dF/dtmax) Rate-of-tension development. (G: dF/dtmin) Rate-of-tension relaxation in H2-TG left atrial preparations. Ordinates in (A–C): force of contraction in milli-Newton (mN). Ordinate in (D) time to peak tension in milli seconds (ms). Ordinate in (E) time of relaxation in milli seconds (ms). Ordinate in (F) rate of contraction in mN/s and ordinate in (G) rate of relaxation in mN/s. Horizontal bars in (A,B) indicate time in minutes (min). Abscissae in (D–F) indicate concentrations of ergotamine or histamine in negative decadic logarithm of molar concentrations. * p < 0.05 vs. Ctr, first significant difference versus control (pre-drug value, Ctr). “n” indicates number of experiments given in brackets.
Ijms 24 04749 g002aIjms 24 04749 g002bIjms 24 04749 g002cIjms 24 04749 g002d
Ijms 24 04749 g003 550
Figure 3. Ergotamine increases frequency in H2-TG: (A) Original recording of beating rate in H2-TG right atrium. Original recording: effect of ergotamine and histamine on beating rate in spontaneously beating right atrial preparations from H2-TG. The blue lines indicate duration of transient arrhythmias. Blue triangle mean addition of ergotamine and black triangles indicate addition of histamine. (A). Summarized effect of ergotamine and histamine on beating rate in spontaneously beating right atrial preparations from H2-TG (B). Ordinate in (A): beating rate in beats per minute (bpm). Ordinate in (B) in beating rate in beats pro minute (bpm). Abscissae in in (A,B), of ergotamine or histamine in negative decadic logarithms of molar concentrations. Horizontal bar in A indicates time axis in minutes (min). First significant differences versus control (Ctr; pre-drug value) are indicated by asterisks. “n” indicates number of experiments.
Figure 3. Ergotamine increases frequency in H2-TG: (A) Original recording of beating rate in H2-TG right atrium. Original recording: effect of ergotamine and histamine on beating rate in spontaneously beating right atrial preparations from H2-TG. The blue lines indicate duration of transient arrhythmias. Blue triangle mean addition of ergotamine and black triangles indicate addition of histamine. (A). Summarized effect of ergotamine and histamine on beating rate in spontaneously beating right atrial preparations from H2-TG (B). Ordinate in (A): beating rate in beats per minute (bpm). Ordinate in (B) in beating rate in beats pro minute (bpm). Abscissae in in (A,B), of ergotamine or histamine in negative decadic logarithms of molar concentrations. Horizontal bar in A indicates time axis in minutes (min). First significant differences versus control (Ctr; pre-drug value) are indicated by asterisks. “n” indicates number of experiments.
Ijms 24 04749 g003
Ijms 24 04749 g004a 550Ijms 24 04749 g004b 550Ijms 24 04749 g004c 550Ijms 24 04749 g004d 550
Figure 4. Ergotamine increases force in 5-HT4-TG. (A) Original recording in mouse left atrial preparations from 5-HT4-TG. It becomes apparent that ergotamine induced a time- and concentration-dependent positive inotropic effect. (B) Original recordings in mouse left atrial preparations from WT. It becomes apparent that ergotamine did not induce a time- and concentration-dependent positive inotropic effect. (C) Summarized concentration–response curves for the effect of ergotamine or histamine on force of contraction. (D: T1) Time to peak tension. (E: T2) Time to relaxation. (F: dF/dtmax) Rate-of-tension development. (G: dF/dtmin) Rate-of-tension relaxation in 5-HT4-TG left atria. * p < 0.05 vs. Ctr, first significant difference versus control (pre-drug value, Ctr). Ordinates in (A–C): force of contraction in milli-Newton (mN). Ordinate in (D) time to peak tension in milli seconds (ms). Ordinate in (E) time of relaxation in milli seconds (ms). Ordinate in (F) rate of contraction in mN/s and ordinate in (G) rate of relaxation in mN/s. Horizontal bars in (A,B) indicate time in minutes (min). Abscissae in (D–F) indicate concentrations of ergotamine or histamine in negative decadic molar concentrations. Significant differences versus control (CTR; pre-drug value) is indicated in asterisks. “n” indicates number of experiments.
Figure 4. Ergotamine increases force in 5-HT4-TG. (A) Original recording in mouse left atrial preparations from 5-HT4-TG. It becomes apparent that ergotamine induced a time- and concentration-dependent positive inotropic effect. (B) Original recordings in mouse left atrial preparations from WT. It becomes apparent that ergotamine did not induce a time- and concentration-dependent positive inotropic effect. (C) Summarized concentration–response curves for the effect of ergotamine or histamine on force of contraction. (D: T1) Time to peak tension. (E: T2) Time to relaxation. (F: dF/dtmax) Rate-of-tension development. (G: dF/dtmin) Rate-of-tension relaxation in 5-HT4-TG left atria. * p < 0.05 vs. Ctr, first significant difference versus control (pre-drug value, Ctr). Ordinates in (A–C): force of contraction in milli-Newton (mN). Ordinate in (D) time to peak tension in milli seconds (ms). Ordinate in (E) time of relaxation in milli seconds (ms). Ordinate in (F) rate of contraction in mN/s and ordinate in (G) rate of relaxation in mN/s. Horizontal bars in (A,B) indicate time in minutes (min). Abscissae in (D–F) indicate concentrations of ergotamine or histamine in negative decadic molar concentrations. Significant differences versus control (CTR; pre-drug value) is indicated in asterisks. “n” indicates number of experiments.
Ijms 24 04749 g004aIjms 24 04749 g004bIjms 24 04749 g004cIjms 24 04749 g004d
Ijms 24 04749 g005 550
Figure 5. Ergotamine increases frequency in 5-HT4-TG. (A) Original recording: effect of ergotamine and serotonin on beating rate in spontaneously beating right atrial preparations from 5-HT4-TG. (B): Summarized effect of ergotamine or serotonin on beating rate in spontaneously beating right atrial preparations from 5-HT4-TG. Abscissae in (B) give concentrations of ergotamine or histamine in negative decadic logarithms, respectively. Horizontal bar in (A) indicates time axis in minutes (min). In (B) first significant differences versus control (Ctr; pre-drug value) is indicated in asterisks. “n” indicates number of experiments.
Figure 5. Ergotamine increases frequency in 5-HT4-TG. (A) Original recording: effect of ergotamine and serotonin on beating rate in spontaneously beating right atrial preparations from 5-HT4-TG. (B): Summarized effect of ergotamine or serotonin on beating rate in spontaneously beating right atrial preparations from 5-HT4-TG. Abscissae in (B) give concentrations of ergotamine or histamine in negative decadic logarithms, respectively. Horizontal bar in (A) indicates time axis in minutes (min). In (B) first significant differences versus control (Ctr; pre-drug value) is indicated in asterisks. “n” indicates number of experiments.
Ijms 24 04749 g005
Ijms 24 04749 g006 550
Figure 6. Ergotamine increases the phosphorylation state of phospholamban: contracting preparations as seen in Figure 2 and Figure 4 were freeze-clamped after the addition of ergotamine 10 µM (see fourth row in the table below the Western blot). This was done with left atrial preparations from wild type mice (WT) as negative control, and also in atrial preparations from 5-HT4-TG or H2-TG as indicated by “+”. No additional histamine or serotonin was added. Typical Western blots are seen. Western blots depict serine 16 phosphorylated phospholamban (PLB) with arrows. As a loading control, we assessed the protein expression of calsequestrin (CSQ) by cutting the lanes of the blot horizontally and incubating the lower and upper halves with different primary antibodies. Relevant molecular weight markers are indicated with arrows and marked with kilodalton (kDa). As a positive control, samples from atrium treated with 10 µM isoprenaline are shown in the middle. Boiled means that the isoprenaline-treated atrium was brought to the temperature of 95 °C for 10 min and was then rapidly loaded on this original gel. Please note the mobility shift in the boiled sample confirming that we really detected phospholamban. In the middle row (empty), we allowed the molecular weight marker to run.
Figure 6. Ergotamine increases the phosphorylation state of phospholamban: contracting preparations as seen in Figure 2 and Figure 4 were freeze-clamped after the addition of ergotamine 10 µM (see fourth row in the table below the Western blot). This was done with left atrial preparations from wild type mice (WT) as negative control, and also in atrial preparations from 5-HT4-TG or H2-TG as indicated by “+”. No additional histamine or serotonin was added. Typical Western blots are seen. Western blots depict serine 16 phosphorylated phospholamban (PLB) with arrows. As a loading control, we assessed the protein expression of calsequestrin (CSQ) by cutting the lanes of the blot horizontally and incubating the lower and upper halves with different primary antibodies. Relevant molecular weight markers are indicated with arrows and marked with kilodalton (kDa). As a positive control, samples from atrium treated with 10 µM isoprenaline are shown in the middle. Boiled means that the isoprenaline-treated atrium was brought to the temperature of 95 °C for 10 min and was then rapidly loaded on this original gel. Please note the mobility shift in the boiled sample confirming that we really detected phospholamban. In the middle row (empty), we allowed the molecular weight marker to run.
Ijms 24 04749 g006
Ijms 24 04749 g007 550
Figure 7. Ergotamine increases force in human atrium: original recording of the effect of 10 µM ergotamine (Ergo), 10 µM tropisetron (Tropi) and 10 µM cimetidine (Cime) in the presence of 1 µM cilostamide (Cilo) on HAP.
Figure 7. Ergotamine increases force in human atrium: original recording of the effect of 10 µM ergotamine (Ergo), 10 µM tropisetron (Tropi) and 10 µM cimetidine (Cime) in the presence of 1 µM cilostamide (Cilo) on HAP.
Ijms 24 04749 g007
Ijms 24 04749 g008 550
Figure 8. Effects of subsequently applied cilostamide (Cilo, 1 µM), then additionally ergotamine (10 µM), tropisetron (Tropi, 10 µM) and cimetidine (Cime, 10 µM) on force of contraction in isolated electrically stimulated human right atrial preparations. Compare with Figure 7 for the order of drug application. Numbers in brackets indicate the number of muscle strips studied. Force of contraction was calculated by setting the maximum effect of cilostamide as one hundred percent (100% compare Figure 7). * or # indicate significant differences (p < 0.05) against Cilo or Cime, respectively.
Figure 8. Effects of subsequently applied cilostamide (Cilo, 1 µM), then additionally ergotamine (10 µM), tropisetron (Tropi, 10 µM) and cimetidine (Cime, 10 µM) on force of contraction in isolated electrically stimulated human right atrial preparations. Compare with Figure 7 for the order of drug application. Numbers in brackets indicate the number of muscle strips studied. Force of contraction was calculated by setting the maximum effect of cilostamide as one hundred percent (100% compare Figure 7). * or # indicate significant differences (p < 0.05) against Cilo or Cime, respectively.
Ijms 24 04749 g008
Table
Table 1. Maximum effect of ergotamine (10 µM) on force of contraction in milli-Newton (mN) and the rate-of-tension relaxation mN/seconds (mN/s) in isolated perfused hearts from H2-TG, 5-HT4-TG and WT. # indicate p < 0.05 versus pre-drug (ergotamine) value. N = number of animals.
Table 1. Maximum effect of ergotamine (10 µM) on force of contraction in milli-Newton (mN) and the rate-of-tension relaxation mN/seconds (mN/s) in isolated perfused hearts from H2-TG, 5-HT4-TG and WT. # indicate p < 0.05 versus pre-drug (ergotamine) value. N = number of animals.
WTH2-TG5-HT4-TG
N=774
Basal force (mN)11.3 ± 1.211.3 ± 1.514.9 ± 2.1
Force after ergotamine (mN)12.3 ± 1.215.8 ± 1.8 #18.5 ± 2.9 #
Basal rate of relaxation (mN/s)224 ± 14.1208 ± 28.4218 ± 14.0
Rate of relaxation after ergotamine (mN/s)250 ± 18.6315 ± 44.8 #287 ± 27.8 #
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jacob, H.; Braekow, P.; Schwarz, R.; Höhm, C.; Kirchhefer, U.; Hofmann, B.; Neumann, J.; Gergs, U. Ergotamine Stimulates Human 5-HT4-Serotonin Receptors and Human H2-Histamine Receptors in the Heart. Int. J. Mol. Sci. 2023, 24, 4749. https://doi.org/10.3390/ijms24054749

AMA Style

Jacob H, Braekow P, Schwarz R, Höhm C, Kirchhefer U, Hofmann B, Neumann J, Gergs U. Ergotamine Stimulates Human 5-HT4-Serotonin Receptors and Human H2-Histamine Receptors in the Heart. International Journal of Molecular Sciences. 2023; 24(5):4749. https://doi.org/10.3390/ijms24054749

Chicago/Turabian Style

Jacob, Hannes, Pauline Braekow, Rebecca Schwarz, Christian Höhm, Uwe Kirchhefer, Britt Hofmann, Joachim Neumann, and Ulrich Gergs. 2023. "Ergotamine Stimulates Human 5-HT4-Serotonin Receptors and Human H2-Histamine Receptors in the Heart" International Journal of Molecular Sciences 24, no. 5: 4749. https://doi.org/10.3390/ijms24054749

APA Style

Jacob, H., Braekow, P., Schwarz, R., Höhm, C., Kirchhefer, U., Hofmann, B., Neumann, J., & Gergs, U. (2023). Ergotamine Stimulates Human 5-HT4-Serotonin Receptors and Human H2-Histamine Receptors in the Heart. International Journal of Molecular Sciences, 24(5), 4749. https://doi.org/10.3390/ijms24054749

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop